Tuesday, 02 January 2024 12:17 GMT

Neuroone(R) To Report Fourth Quarter And Fiscal Year 2025 Financial Results On Wednesday, December 17Th At 8:30 A.M. Eastern Time


(MENAFN- EQS Group)

NeuroOne Medical Technologies / Key word(s): Financial
NeuroOne(R) to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Wednesday, December 17th at 8:30 a.m. Eastern Time
11.12.2025 / 22:04 CET/CEST
The issuer is solely responsible for the content of this announcement.

EDEN PRAIRIE, MINN. - December 11, 2025 (NEWMEDIAWIRE ) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal fourth quarter and year ended September 30, 2025, before market open on December 17, 2025.

Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Wednesday, December 17, 2025, to discuss the Company's fourth quarter and full fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:

Fiscal Fourth Quarter 2025 Earnings Conference Call
Date: Wednesday, December 17, 2025
Time: 8:30 a.m. Eastern time
U.S. Dial-In (Toll Free): 888-506-0062
International Dial-In: 973-528-0011
Participant Access Code: 924910
Webcast: NMTC FY Q4 2025 Earnings Call Webcast

Please join at least five minutes before the start of the call to ensure timely participation

A playback of the call will be available through Wednesday, December 31, 2025. To listen to the replay, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay passcode 53302. A webcast replay will also be available using the webcast link above through Wednesday, December 31, 2025.

About NeuroOne

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit

IR Contact
MZ Group - MZ North America
...

View the original release on


News Source: NeuroOne Medical Technologies

11.12.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Language: English
Company: NeuroOne Medical Technologies
United States
ISIN: US64130M2098
EQS News ID: 2244470

End of News EQS News Service

2244470 11.12.2025 CET/CEST

MENAFN11122025004691010666ID1110470683



EQS Group

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Search